Liquidia Corporation (LQDA)
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
Liquidia shares surge 25% as settlement ends United Therapeutics litigation
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
LQDA faces a major setback as a patent ruling threatens Yutrepia's PH-ILD indication and creates uncertainty around its commercial outlook.
Liquidia: Bullish On Their Growth Potential Despite YUTREPIA's Legal Tail Risk
YUTREPIA's adoption is translating into profits and cash, giving Liquidia an operating foundation for further growth. LQDA is already generating substantial cash flows, even though YUTREPIA's growth phase remains in its early stages. The main risk I believe is worth monitoring is LQDA's ongoing legal battle with UTHR over potential patent infringement.
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Is the Options Market Predicting a Spike in Liquidia Stock?
Investors need to pay close attention to LQDA stock based on the movements in the options market lately.
Liquidia: A Linear Launch Priced For Exponential Growth
Liquidia Corporation is rated Sell due to YUTREPIA's decelerating growth and an overextended $6B+ valuation. YUTREPIA's percentage growth is compressing, prescriber acquisition has halved, and launch-era tailwinds are fading. Future growth will require difficult community penetration and overcoming structural headwinds from patient mortality and discontinuation.
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
